AstraZeneca Pharma India Limited (ASTRAZEN.NS)
INR 8062.25
(2.46%)
INR 8062.25
(2.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.47 Billion INR | 79.36% |
| 2022 | 945.08 Million INR | 16.02% |
| 2021 | 814.6 Million INR | -35.55% |
| 2020 | 1.26 Billion INR | 10.08% |
| 2019 | 1.14 Billion INR | 103.65% |
| 2018 | 563.8 Million INR | 65.19% |
| 2017 | 341.3 Million INR | 73.51% |
| 2016 | 196.7 Million INR | 2964.22% |
| 2015 | -6.86 Million INR | 97.38% |
| 2014 | -262.6 Million INR | -16.21% |
| 2013 | -225.97 Million INR | 71.99% |
| 2012 | -806.71 Million INR | -436.27% |
| 2011 | 239.9 Million INR | -74.85% |
| 2010 | 954.07 Million INR | 6.44% |
| 2009 | 896.34 Million INR | -15.24% |
| 2008 | 1.05 Billion INR | 23.07% |
| 2007 | 859.26 Million INR | 14.64% |
| 2006 | 749.51 Million INR | 15.71% |
| 2005 | 647.76 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 341.6 Million INR | -25.13% |
| 2023 Q3 | 210.12 Million INR | -63.43% |
| 2023 Q4 | 456.24 Million INR | 117.13% |
| 2023 Q1 | 715.51 Million INR | 206.19% |
| 2023 FY | 1.69 Billion INR | 79.36% |
| 2023 Q2 | 574.58 Million INR | -19.7% |
| 2022 FY | 945.08 Million INR | 16.02% |
| 2022 Q4 | 233.68 Million INR | -41.07% |
| 2022 Q1 | 274.87 Million INR | -20.82% |
| 2022 Q2 | 442.31 Million INR | 60.92% |
| 2022 Q3 | 396.52 Million INR | -10.35% |
| 2021 Q2 | 136.6 Million INR | 25.67% |
| 2021 Q4 | 347.14 Million INR | 110.49% |
| 2021 FY | 814.6 Million INR | -35.55% |
| 2021 Q1 | 108.7 Million INR | -69.36% |
| 2021 Q3 | 164.91 Million INR | 20.73% |
| 2020 Q2 | 411.44 Million INR | 71.36% |
| 2020 FY | 1.26 Billion INR | 10.08% |
| 2020 Q1 | 240.1 Million INR | 124.11% |
| 2020 Q4 | 354.82 Million INR | 38.42% |
| 2020 Q3 | 256.33 Million INR | -37.7% |
| 2019 Q3 | 319.92 Million INR | 10.63% |
| 2019 Q4 | 107.13 Million INR | -66.51% |
| 2019 Q2 | 289.19 Million INR | -6.52% |
| 2019 Q1 | 309.35 Million INR | 1156.05% |
| 2019 FY | 1.14 Billion INR | 103.65% |
| 2018 Q2 | 110.89 Million INR | 93.56% |
| 2018 Q4 | 24.62 Million INR | -93.36% |
| 2018 FY | 563.8 Million INR | 65.19% |
| 2018 Q1 | 57.29 Million INR | -51.11% |
| 2018 Q3 | 370.98 Million INR | 234.55% |
| 2017 Q2 | 343.96 Million INR | 1270.99% |
| 2017 FY | 341.3 Million INR | 73.51% |
| 2017 Q4 | 117.18 Million INR | 199.17% |
| 2017 Q3 | -118.16 Million INR | -134.35% |
| 2017 Q1 | 25.08 Million INR | 225.99% |
| 2016 Q1 | 119.02 Million INR | 1020.75% |
| 2016 Q4 | -19.91 Million INR | -118.23% |
| 2016 FY | 196.7 Million INR | 2964.22% |
| 2016 Q2 | -8.39 Million INR | -107.05% |
| 2016 Q3 | 109.22 Million INR | 1401.17% |
| 2015 Q3 | 86.74 Million INR | 229.68% |
| 2015 Q2 | -66.89 Million INR | -346.24% |
| 2015 Q1 | 27.16 Million INR | -91.69% |
| 2015 Q4 | 10.62 Million INR | -87.76% |
| 2015 FY | -6.86 Million INR | 97.38% |
| 2014 Q3 | -134.09 Million INR | 52.04% |
| 2014 Q1 | -176 Million INR | 30.05% |
| 2014 Q2 | -279.6 Million INR | -58.86% |
| 2014 FY | -262.6 Million INR | -16.21% |
| 2014 Q4 | 327.08 Million INR | 343.93% |
| 2013 FY | -225.97 Million INR | 71.99% |
| 2013 Q2 | -7.17 Million INR | -140.57% |
| 2013 Q1 | 17.68 Million INR | 106.1% |
| 2013 Q3 | 15.17 Million INR | 311.55% |
| 2013 Q4 | -251.59 Million INR | -1757.55% |
| 2012 FY | -806.71 Million INR | -436.27% |
| 2012 Q4 | -289.76 Million INR | -63.75% |
| 2012 Q3 | -176.95 Million INR | 14.99% |
| 2012 Q2 | -208.16 Million INR | -57.9% |
| 2012 Q1 | -131.83 Million INR | 75.69% |
| 2011 FY | 239.9 Million INR | -74.85% |
| 2011 Q3 | 219.99 Million INR | 0.0% |
| 2011 Q4 | -542.21 Million INR | -346.46% |
| 2010 FY | 954.07 Million INR | 6.44% |
| 2009 FY | 896.34 Million INR | -15.24% |
| 2008 FY | 1.05 Billion INR | 23.07% |
| 2007 FY | 859.26 Million INR | 14.64% |
| 2006 FY | 749.51 Million INR | 15.71% |
| 2005 FY | 647.76 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aarti Drugs Limited | 7.14 Billion INR | 37.417% |
| Albert David Limited | 1.33 Billion INR | -235.26% |
| Alembic Limited | 767.77 Million INR | -482.714% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -21559.082% |
| Hester Biosciences Limited | 364.77 Million INR | -1126.499% |
| Hikal Limited | 1.49 Billion INR | -199.418% |
| Ind-Swift Limited | 1.22 Billion INR | -264.929% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2050.397% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 22.302% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -1782.471% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | -72.25 Million INR | 6292.078% |
| Eris Lifesciences Limited | 5.18 Billion INR | 13.66% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 216.118% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -1990.217% |
| Wanbury Limited | 1.7 Billion INR | -162.06% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -43.022% |
| Alkem Laboratories Limited | 19.46 Billion INR | 77.012% |
| FDC Limited | 3.03 Billion INR | -47.471% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 50.175% |
| Gufic Biosciences Limited | 2.89 Billion INR | -54.603% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -122.689% |
| Innova Captab Limited | 2.53 Billion INR | -76.596% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 9.476% |
| Ipca Laboratories Limited | 29.59 Billion INR | 84.884% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 13.781% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -134.687% |
| Lupin Limited | 27.75 Billion INR | 83.883% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -16193.612% |
| Medico Remedies Limited | 277.11 Million INR | -1514.439% |
| Morepen Laboratories Limited | 4.17 Billion INR | -7.189% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -14.993% |
| Orchid Pharma Limited | 2.36 Billion INR | -89.485% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -60.585% |
| RPG Life Sciences Limited | 2.29 Billion INR | -95.171% |
| Sigachi Industries Limited | 1.47 Billion INR | -203.542% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.711% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 2.903% |
| Themis Medicare Limited | 1.3 Billion INR | -243.326% |
| Vaishali Pharma Limited | 6.29 Million INR | -70981.983% |
| Venus Remedies Limited | 534.65 Million INR | -736.789% |
| Windlas Biotech Limited | 1.29 Billion INR | -244.44% |
| ZIM Laboratories Limited | 1.09 Billion INR | -307.417% |
| Sakar Healthcare Limited | 495.5 Million INR | -802.895% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 95.719% |
| Divi's Laboratories Limited | 18.31 Billion INR | 75.566% |
| Mankind Pharma Limited | 40.86 Billion INR | 89.053% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | -13.303% |
| Neuland Laboratories Limited | 5.31 Billion INR | 15.874% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 40.677% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 31.196% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 90.144% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -620.403% |
| Wockhardt Limited | 140 Million INR | -3095.643% |
| Bal Pharma Limited | 214.56 Million INR | -1985.064% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 93.394% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -263.436% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -711.093% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 38.08% |
| Shilpa Medicare Limited | 3.76 Billion INR | -18.937% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 77.264% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -157942.211% |
| Granules India Limited | 6.52 Billion INR | 31.469% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1694.938% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 82.341% |
| NATCO Pharma Limited | 25.96 Billion INR | 82.768% |
| Suven Life Sciences Limited | -1.22 Billion INR | 464.971% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 14.388% |
| Indoco Remedies Limited | 1.52 Billion INR | -193.486% |
| Alpa Laboratories Limited | 61.51 Million INR | -7172.86% |
| Lasa Supergenerics Limited | -458 Million INR | 1076.823% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 208.721% |